WCLC 2025 - Posters & ePosters-P3.13.28 Survival Outcomes in Advanced Large Cell Neuroendocrine Carcinoma of the Lung in Immunotherapy Era: An NCDB Analysis

P3.13.28 Survival Outcomes in Advanced Large Cell Neuroendocrine Carcinoma of the Lung in Immunotherapy Era: An NCDB Analysis

Back to course

Pdf Summary

This study analyzed survival outcomes for patients with advanced large cell neuroendocrine carcinoma (LCNEC) of the lung in the era of immunotherapy, using data from the National Cancer Database (NCDB) for stage IV cases diagnosed between 2015 and 2020. The cohort included 2,014 LCNEC patients receiving systemic first-line therapy: 69% received chemotherapy alone, 2% immunotherapy alone, and 29% combined chemoimmunotherapy (chemoIO). Survival was compared to stage IV non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients from the same period.<br /><br />Results showed that LCNEC patients treated with chemoimmunotherapy had a modestly improved median overall survival (mOS) of 10 months versus 8.5 months with chemotherapy alone (hazard ratio [HR] 0.82, p=0.006). Despite this benefit, LCNEC survival remained inferior to NSCLC for both chemotherapy (mOS 8.5 vs. 11.4 months, HR 0.74, p<0.001) and chemoIO (mOS 10 vs. 12.9 months, HR 0.75, p<0.001). Compared to SCLC, LCNEC showed a marginally longer survival with chemotherapy (mOS 8.5 vs. 8.4 months, HR 1.13, p<0.001), but no significant difference with chemoimmunotherapy (mOS 10 vs. 9.6 months, HR 0.08, p=0.1).<br /><br />The authors conclude that while chemoimmunotherapy modestly improves LCNEC outcomes, survival remains worse than NSCLC and comparable to SCLC. They recommend future studies incorporate PD-L1 expression and genomic profiling to optimize treatment strategies and identify ideal chemotherapy partners. This comparative analysis underscores the aggressive nature of LCNEC and highlights the need for targeted therapeutic advancements.

Asset Subtitle

Tina Roy

Meta Tag

Speaker Tina Roy

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

large cell neuroendocrine carcinoma

LCNEC

immunotherapy

chemoimmunotherapy

chemotherapy

non-small cell lung cancer

NSCLC

small cell lung cancer

SCLC

overall survival